Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Author:
Affiliation:
1. Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station.
2. Department of Obstetrics, Gynecology and Predictive Sciences, The University of Texas Health Science Center at Houston.
Publisher
Academy of Managed Care Pharmacy
Subject
Health Policy,Pharmaceutical Science,Pharmacy
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Differences in time to patient access to innovative cancer medicines in six European countries;International Journal of Cancer;2023-10-20
2. Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China;Frontiers in Pharmacology;2023-07-27
3. The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2023-02-03
4. Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China;Frontiers in Pharmacology;2023-01-04
5. Cost-effectiveness of PARP inhibitors in malignancies: A systematic review;PLOS ONE;2022-12-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3